AbbVie’s upadacitinib meets primary endpoint in Phase 2b trial in vitiligo
In the trial, Rinvoq showed a percent change from baseline in the Facial Vitiligo Area Scoring Index at…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
13 Oct 23
In the trial, Rinvoq showed a percent change from baseline in the Facial Vitiligo Area Scoring Index at…
12 Oct 23
As per the results, the investigational twice-yearly, 10-minute subcutaneous injection was found non-inferior as measured by Ocrevus levels…
12 Oct 23
Lisburn based Cirdan, is a global leader in digital pathology with clients in over 150 laboratories and hospitals…
11 Oct 23
The collaboration will leverage BioMap’s AI drug discovery platform, which integrates large language models and super-scale computing with…
11 Oct 23
MEDICA HEALTH IT FORUM shines a light on general trends within digitalisation and their potential for application in…
11 Oct 23
The transaction is subject to customary regulatory and anti-trust approvals
10 Oct 23
The Bill & Melinda Gates Foundation will provide $20m to Quantoom Biosciences to further advance the mRNA technology,…
09 Oct 23
The deal has secured clearance from the US Federal Trade Commission which prohibits Amgen from using any anti-competitive…
09 Oct 23
The FDA has cleared Cosentyx as the first IV formulation interleukin-17A antagonist for adults with psoriatic arthritis, ankylosing…
09 Oct 23
TOFIDENCE is the first monoclonal antibody drug researched, developed, and manufactured by a Chinese pharmaceutical company to receive…